Terence Flynn, an analyst from Morgan Stanley, maintained the Sell rating on Bristol-MyersSquibb (BMY – Research Report). The associated price target remains the same with $37.00. Terence Flynn ...
Recent results from BristolMyersSquibb support an improving outlook. The company is benefiting from strong demand for its new medications. The stock looks attractive, trading at just 7 times ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...